The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
In our population, PAL emerged as a pan-cancer determinant of outcome to TT. Our findings support refined patient selection for TT and highlight the rationale for combinatorial treatment strategies in patients with multiple affected pathways.
Authors
- Laurien J. Zeverijn (ORCID: https://orcid.org/0009-0001-1124-7987)
- Hans A. J. Gelderblom (ORCID: https://orcid.org/0000-0001-9270-8636)
- Paul Roepman (ORCID: https://orcid.org/0000-0003-1566-0258)
- Vincent van der Noort (ORCID: https://orcid.org/0000-0002-4910-4535)
- Birgit S. Geurts (ORCID: https://orcid.org/0009-0007-7205-0890)
- Karlijn Verkerk (ORCID: https://orcid.org/0000-0002-5882-4980)
- H.M.W. Verheul
- Louisa R. Hoes (ORCID: https://orcid.org/0000-0002-6256-3541)
- Anne M.L. Jansen (ORCID: https://orcid.org/0000-0002-8793-0563)
- Emile E. Voest (ORCID: https://orcid.org/0000-0001-8249-9586)
- Jade M. van Berge Henegouwen (ORCID: https://orcid.org/0000-0002-4112-9105)
- Hanneke van der Wijngaart (ORCID: https://orcid.org/0000-0002-0506-8413)
- Joris van de Haar (ORCID: https://orcid.org/0000-0001-5899-3971)
- Wendy W.J. de Leng (ORCID: https://orcid.org/0000-0003-2911-6018)
- A C Spiekman
Institutions
- Radboud University Nijmegen (NL)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Erasmus MC (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Cancer Genomics Centre (NL)
- Hartwig Medical Foundation (NL)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104112
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Clovis Oncology
- Eisai